Phase 2 N=54 A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts
Plantar Warts
Primary: Lesion Assessment — 8.42; 9.14; 8.42; 8.71 millimeters — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
Warts · Plantar Wart · Common Wart
Primary: Diameter of the Wart — -0.12 cm
Phase 3 N=503 Study of A-101 Topical Solution for the Treatment of Common Warts
Common Wart
Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…
N/A N=24 Nanopulse Efficacy Study for the Treatment of Common Warts
Common Warts
Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts
Phase 3 N=426 Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Common Wart
Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants
Phase 3 N=502 A Study of A-101 Topical Solution for the Treatment of Common Warts
Common Wart
Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…
Phase 2 N=77 Intralesional Vitamin D Injection for Treatment of Common Warts
Warts
Primary: Complete Regression of Wart — 12; 10 Participants
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
Phase 2 N=157 A Phase2 of A-101 Topical Solution in Subjects With Common Warts
Common Wart
Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)
Phase 4 N=17 Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Verruca Vulgaris · Molluscum Contagiosum Skin Infection
Primary: Numbers of Lesions With no Response — 8; 9 lesions — p=0.534
N/A N=5 Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
Papillomavirus Infections · Warts · Condylomata Acuminata
Primary: Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint
Phase 1 N=18 Study With Candida Antigen for Treatment of Warts
Warts · HPV
Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants
Phase 3 N=484 A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Cutaneous Common Warts
Primary: Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Phase 2 N=159 A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
Common Wart
Primary: Physician's Wart Assessment — 1.52; 2.23 score on a scale
Phase 2 N=98 A Study of A-101 Solution in Subjects With Common Warts.
Common Warts
Primary: Efficacy Based on Mean Change in Physician Wart Assessment Over Time — -0.38; -1.00; -0.44 units on a scale — p=0.555
Phase 3 N=491 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Cutaneous Common Warts
Primary: The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Phase 2 N=2 Intralesional HPV Vaccine for Condylomata
Human Papilloma Virus · Warts · Warts, Genital
Primary: Change in Wart Number — 0.5 warts
Phase 2 N=39 Candin Safety & Efficacy Study for the Treatment of Warts
Warts · Human Papilloma Virus
Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
Phase 2 N=169 Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Warts
Primary: Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit — 16; 29; 31; 29 Participants — p=0.0329
Phase 4 N=28 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
Verruca, Warts
Primary: Size of Verrucae (Warts) — 2.333; 3.889 millimeters — p=0.383
N/A N=124 CellFX System for the Treatment of Cutaneous Non-Genital Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
N/A N=94 Acupuncture for Plantar Fasciosis in the Primary Care Setting
Plantar Fascitis
Primary: NPRS-11 — 3.8; 4.3; 3.7; 3.1 score on a scale
Phase 2 N=59 Treatment of Oral Warts in HIV+ Patients
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Phase 2 N=183 A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts
Common Warts
Primary: Complete Resolution of All Treated Warts by or at Week 12 — 2; 5; 2; 3 Participants
N/A N=30 Efficacy of Dry Needling in Plantar Fasciitis
Fasciitis, Plantar
Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters
N/A N=77 A Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain
Plantar Fasciitis
Primary: Heel Pain — 26.3; 27.9; 26.6; 23.9 score on a survey — p=0.78
Phase 1 N=41 Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis
Chronic Plantar Fasciitis
Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale
N/A N=3 Peak Plantar Pressures While Wearing a Carbon Fiber Off Loading Orthoses
Diabetes Mellitus · Peripheral Neuropathy · Orthotic Device
Primary: Peak Plantar Pressure — 75.3; 14.2; 14.5; 22.8 Newtons per squared centimeters
N/A N=150 CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Warts Resolved — 80.7; 73.1 percentage of warts resolved